REGULATORY REQUIREMENTS FOR ANTIHYPERTENSIVE DRUGS IN INDIA AS PER CDSCO IN COMPARISON WITH RUSSIA

Hypertension is a significant health issue in India and Russia and is associated with considerable reduction in adverse cardiovascular disease outcomes. To decrease the prevalence of the hypertension by 25% in 2025 and expedite access to treatment services, the India hypertension control initiative (IHCI) was established. To enhance hypertension management in public sector clinics, the IHCI project was introduced in 2018-2019 in 26 districts in five Indian states: Punjab, Madhya Pradesh, Kerala, Maharashtra, Telangana.[1] Both India (CDSCO) and Russia (Minzdrav), face significant public health issues related to hypertension, with 25-30 and 40.1% respectively. The two countries face serious public health challenges. India has great strides towards controlling hypertension and improving regulatory policies. The prevalence in both countries varied significantly between urban and rural areas as well as between specific demographic groups. In India, hypertension affects significant portion of the adult population. Estimates suggest that at least in four adults in India has hypertension, with variations between urban and rural areas. Specifically, urban areas tend to have higher prevalence rates compared to rural areas with 25% and 10-15% respectively.[6] In Russia, hypertension prevalence is generally higher in rural areas compared to urban areas with 63.4% and 44.2% respectively. In both countries treatment and awareness are especially crucial. With greater percentage of people suffering from hypertension, it is a serious problem in both the countries. This paper examines and compares the regulatory requirements concerning hypertension in two countries.